Robert von Rosen is a partner in the Basel office of Walder Wyss. His practice focuses on domestic and international M&A transactions (mainly private M&A/private equity and venture capital) with a focus on telecommunication, energy and life sciences. In addition, he advises mainly medium-sized and start-up companies and SMEs on questions of corporate governance, compliance, restructuring and all other legal aspects of day-to-day business operations. Robert von Rosen is a board member of several corporations and foundations (e.g. Optiswiss Ltd, Holle baby food Ltd. GRS Wieland Foundation).

After completing an apprenticeship in banking, Robert von Rosen studied at the Albert-Ludwigs-University Freiburg, Germany (law exam 2004, bar exam 2006). During that time, he worked as scientific assistant at the professorship in civil law, industrial property protection and copyright law. Before joining Walder Wyss, Robert von Rosen worked for eight years at a leading Swiss law firm, supplemented by a secondment with the Swiss Financial Market Supervisory Authority FINMA.

Robert von Rosen practices in German and English. He is registered with the Basel bar registry and is also admitted to the bar in Germany.

Bar Admissions
He is registered with the Basel bar registry.

Significant Accomplishments

Skribble AG completes Series A round of funding

groupe.id joins Elvaston

Elvaston sells Magnolia International AG to GENUI

BioVersys announces successful first closing of CHF 24.2 million Series C financing to develop clinical pipeline of novel AMR therapies

Cawood übernimmt IES Ltd

proLogistik Holding GmbH erwirbt XELOG AG

Dr. Wild & Co. AG verkauft ihr Pharmageschäfts an die Verfora AG

Boehringer Ingelheim kauft NBE-Therapeutics für EUR 1,18 Milliarden

Noema Pharma Serie A-Finanzierungsrunde über CHF 54 Mio.

Synendos Therapeutics CHF 20m Series A Financing

BioVersys Serie B-Finanzierungsrunde über CHF 19 Mio.

Versant Ventures lanciert Matterhorn Biosciences

ImmunOs Therapeutics AG raises CHF 15m in Series A Financing

Lindsay Goldberg übernimmt Bilcare Research Group

GrandVision übernimmt McOptic

Boehringer Ingelheim erwirbt Amal Therapeutics SA

CHF 12.5 Million Finanzierungsrunde bei Alentis Therapeutics AG

NNIT A/S übernimmt Halfmann Goetsch Partner AG

Precision Surfacing Solutions kauft Wafer Geschäft von Meyer Burger

SHS investiert in Schweizer Life-Science-Unternehmen evitria AG

Cellestia Biotech AG: CHF 20 Millionen Series A Finanzierungsrunde

BC Platforms CHF10 Mio. B Runde

RWS acquires LUZ, Inc.

Beförderungen bei Walder Wyss

Spadina House AG erwirbt SkyVision

Acino veräussert sein Geschäft mit transdermalen Pflastern an Luye Pharma Group Ltd.

Bayer und CRISPR Therapeutics gründen Genome Editing Joint Venture

Honeywell übernimmt Aviaso

Energiedienst Holding AG und TRITEC bündeln ihr Know-how

Kauf und Refinanzierung der Boost Holding AG

Avanade erwirbt KCS.net

P&I Personal & Informatik AG übernimmt Geschäftsbereich HR der Soreco AG

SVC-AG für KMU Risikokapital erwirbt Minderheitsbeteiligung an Stratpharma AG

Beförderungen bei Walder Wyss

Kliniken Valens übernimmt Rheinburg-Klinik

Hot Topic: Corporate Governance vs. Social Responsibility of Swiss Companies
OR und HRegV | Modernisierung des Handelsregisterrechts - Auswirkungen auf die Praxis
CO and CRO | Modernisation of the Law on Commercial Registers - Impact on Practice